MYCN is the driving oncogene for NB; however, all the efforts to silence its protein product MYCN have failed because of its structural and biochemical properties, so that MYCN is still considered “un-druggable” [37], despite more recent new scientific and technological improvements that include PROTAC/degrader technology [38]. This evidence concerns the gene MYCN and neuroblastoma.